Targets › ENO1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2027.
Enolase that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in glycolysis and the reverse reaction in gluconeogenesis. Also involved in various processes such as growth control, hypoxia tolerance and allergic responses. (UniProt, P06733)
Open in Phaseline: the race on ENO1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| HuniLife Biotechnology | HuL001 Anti-ENO1 monoclonal antibody | ENO1 | Phase 1 | Multiple Myeloma Refractory | Nov 2027 |
Multiple Myeloma Refractory (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.